Silo Pharma Set To Acquire Exclusive Licensing For Promising Alzheimer’s Disease Therapeutic; SPC-14 Shows Cognitive And Stress Reduction Benefits In Preclinical Models
SPC-14 shows cognitive and stress reduction benefits in preclinical models SARASOTA, FL, April 10, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage